Kventiax Sr

Quetiapine, the active ingredient in Kventiax Sr, is an atypical antipsychotic presented as an oral dosage form for oral use. It is prescribed for the management of schizophrenia, bipolar disorder, and as adjunctive therapy in major depressive disorder, helping to balance neurotransmitter activity in the brain.

GNH USA supplies Kventiax Sr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Quetiapine is an atypical antipsychotic that modulates dopamine and serotonin pathways in several psychiatric conditions. - Schizophrenia: reduces psychotic symptoms such as delusions and hallucinations. - Bipolar disorder: stabilises mood and prevents manic or depressive episodes. - Major depressive disorder (adjunctive): enhances antidepressant response when added to standard therapy.

Quetiapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Drowsiness: increased sedation, especially at treatment initiation. - Dry mouth: reduced salivation causing discomfort. - Constipation: slowed gastrointestinal motility. - Weight gain: modest increase in body weight over time. - Orthostatic hypotension: dizziness upon standing. - Elevated cholesterol: changes in lipid profile.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and muscle rigidity. - Agranulocytosis: severe drop in white blood cells. - Tardive dyskinesia: persistent involuntary movements. - Suicidal thoughts: emergence or worsening of suicidal ideation. - Seizures: lowered seizure threshold in predisposed individuals.

When prescribing quetiapine, clinicians should consider several safety aspects. - Cardiovascular monitoring: watch for orthostatic hypotension and QT prolongation. - Metabolic assessment: regularly check weight, glucose, and lipid levels. - CNS depression: caution patients operating machinery or driving. - Liver function: evaluate hepatic impairment before initiation. - Pregnancy and lactation: assess risk‑benefit ratio; use only if clearly needed. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Quetiapine can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase quetiapine plasma levels. - CNS depressants (e.g., benzodiazepines, opioids): heightened sedation and respiratory depression. - Antihypertensives: additive orthostatic hypotension risk.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce quetiapine exposure. - Anticholinergic agents: may exacerbate dry mouth and constipation. - Lithium: potential for increased neurotoxicity; monitor serum levels.